HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.115720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Na Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. Hauptthemen laut MEDLINE: Ferroptosis, Multiple Myeloma, Ubiquitin Thiolesterase, Amino Acid Transport System y+. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Province Natural Science Foundation, Science and Technology Support Program of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ferroptosis, a regulated cell death triggered by overload-dependent lipid peroxidation, is implicated in multiple human cancers. The mechanisms underlying ferroptosis in multiple myeloma (MM) remain enigmatic. Here, we confirmed that HSPA9 is overexpressed in MM samples and correlates with unfavorable outcomes. Functionally, HSPA9 enhances MM cell viability, ferroptosis resistance, and tumorigenicity, suggesting its oncogenic role. Proteomics screening identified SLC7A11, a key ferroptosis suppressor, as a HSPA9 interactor. Mechanistically, HSPA9 serves as a bridge to strengthen the interaction between USP14 and SLC7A11, modulating USP14-mediated SLC7A11 deubiquitination. Furthermore, the inhibition of USP14 with IU1 enhances the SLC7A11 ubiquitination and degradation, promoting ferroptosis and showing therapeutic efficacy in MM xenograft models. Clinically, HSPA9, USP14, and SLC7A11 expression are positively correlated in MM samples, which have a prognostic value. Our study reveals HSPA9-USP14-SLC7A11 axis as a key regulator of ferroptosis in MM and a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. Electronic address: chenljb@126.com.
Förderung
- Jiangsu Province Natural Science Foundation
- Science and Technology Support Program of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Shen, N., Xia, Y., Shen, X., Hua, W., Shi, M., & Chen, L. (2025). HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115720
Vancouver
Shen N, Xia Y, Shen X, Hua W, Shi M, Chen L. HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115720
BibTeX
@article{Shen2025,
author = {Shen, Na and Xia, Yuan and Shen, Xuxing and Hua, Wei and Shi, Min and Chen, Lijuan},
title = {HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.115720}
}
EUVIMED